Page 539 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

500 MÉDICAMENTS EN RELA TION A VEC DES SYSTÈMES HORMONA UX

LANG M. et al. Structure-activity relationships and binding model of novel aromatase
inhibitors. J. Steroid. Biochem. Molec. Biol., 1993, 44, 421-428.
LAUGHTON C.A. et al. A detailed molecular model for human aromatase. J. Steroid.
Biochem. Molec. Biol., 1993, 44, 399-407.
LONNING P.E. et JOHANNENSON D.C. Treatment of breast cancer with aromatase
inhibitors. Drugs to day. 1991,27, 117-132.
OH S.S. et ROBINSON C.H. Mecanism of human placental aromatase : a new active
site model. J. Steroid. Biochem. Molec. Biol., 1993, 44, 389-397.
PEET N.P. et al. A ring bridged steroids as potent inhibitors of aromatase. J. Steroid.
Biochem. Molec. Biol., 1993, 44, 409-420.
POON G.K. et al. Investigation of conjugated métabolites of 4-hydroxy-androst-4-ene-
3,17-dione in patient urine by liquid chromatography-atmospheric pressure ioniza-
tion mass spectrometry. Drug Metabolism and Disposition, 1992, 20, 941-947.
ROYA C. Formestane, Drugs Fut., 1993, 18, 599-600.
VAN DER WALL E. et al. Inhibition of the in vivo conversion of androstenedione to
estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
Cancer Research, 1993, 53, 4563-4566.
WHOMSLEY R. et al. Substituted 1-[(benzofuran-2-yl)phenylmethyl]-imidazoles as
potent inhibitors of aromatase in vitro and in female rats in vivo. J. Steroid.
Biochem. Molec. Biol., 1993, 44, 675-676.
WISEMAN L.R. et Mc TAVISCH D. Formestane. A review of its pharmacodynamie and
pharmacokinetic properties and therapeutic potential in the management of breast
cancer and prostatic cancer. Drugs, 1993, 45, 66-84.
WOUTERSeta/. Aromatase inhibition by R 76713 : Experimental and clinical pharma-
cology. J. Steroid. Biochem. Molec. Biol., 1989, 34, 427-430.
WOUTERS W. et al. Pharmacology of vorozole. J. Steroid. Biochem. Molec. Biol.,
1993,44,617-621.
WOZNIAK ZA. et HUTCHISON J.B. Action of endogenous steroid inhibitors of brain
aromatase relative to fadrozole. J. Steroid. Biochem. Molec. Biol., 1993, 44, 641­
645.
WOZNIAK A. et al. In vitro potency and selectivity of the non-steroidal androgen aro­
matase inhibitor CGS 16949. J. Steroid. Biochem. Molec. Biol., 1993, 43, 281-287.
ZACCHEO T. et al. A new irréversible aromatase inhibitor, 6-methylen-androsta-1,4-
diene-3,17-dione (FCE 24304) antitumor activity and endocrine effects in rats with
DMBA-induced mammary tumors. Cancer. Chemother. Pharmacol., 1989, 23, 47­
50.
ZACCHEO T. et DI SALLE E. Inhibitory effect of combined treatment with the aroma­
tase inhibitor exemestane and tamoxifen on DBMA-induced mammary tumors in
rats. J. Steroid. Biochem. Molec. Biol., 1993, 44, 667-680.
ZACCHEO T. et DI SALLE E. Antitumor activity of the aromatase inhibitor FCE 24928
on DBMA-induced mammary tumors in ovariectomized rats treated with testoste­
rone. Cancer. Chemother. Pharmacol., 1993, 31, 308-312.
ZIMNISKI S.J. et al. Inhibition of growth and appearance of estrogen-dependent rat
mammary tumors by 10-propargylestr-4-ene-3,17-dione an aromatase inhibitor.
Breast Cancer Res. Treat., 1993, 26, 15-21.